Conférence
Notice
Langue :
Anglais
Crédits
Canal U/3S - CERIMES (Production), Canal U/3S - CERIMES (Réalisation), Wolfgang Koenig (Intervention)
Conditions d'utilisation
Droit commun de la propriété intellectuelle
DOI : 10.60527/cz7f-bf48
Citer cette ressource :
Wolfgang Koenig. Canal-U-Médecine. (2012, 30 novembre). Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 2 : Well Established Methods for Imaging Approaches, IVUS and IMT (Wolfgang KOENIG) , in CVCT 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012. [Vidéo]. Canal-U. https://doi.org/10.60527/cz7f-bf48. (Consultée le 16 mai 2025)
Logo Canal-U/Médecine
Canal-U/Médecine
S'abonner
Contacter

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 2 : Well Established Methods for Imaging Approaches, IVUS and IMT (Wolfgang KOENIG)

Réalisation : 30 novembre 2012 - Mise en ligne : 27 février 2013
  • document 1 document 2 document 3
  • niveau 1 niveau 2 niveau 3
Descriptif

MODIGLIANI Workshop 2 - Friday November 30, 2012 :
ATHEROSCLEROSIS IMAGING IN CLINICAL TRIALS
Facilitating the discovery of effective therapies

Chairpersons: Jagat NARULA, New York, USA - Ahmed TAWAKOL, Boston, USA
Webcast: Bart STAELS, Lille, FRA

Phase III clinical endpoint trials evaluating treatments for atherosclerosis typically require very large sample sizes, cost hundreds of millions of dollars and historically have had very low success rates. As a result, few new therapies that attenuate the progression of atherosclerosis have been identified in over 30 years (since the discovery of statins).
Nearly a decade ago, in recognition of the low success of Phase III trials, regulatory agencies called for the adoption of new biomarkers or surrogate endpoints to enhance the rate of clinical development. To that end, several cardiovascular imaging technologies have gone through evolutionary cycles of validation over the past decade and several have demonstrated promise as clinical tools and as clinical trial biomarkers.
With the rapid development and implementation of these imaging approaches, it is important to delineate the opportunities and limitations associated with these tools. In particular, it is essential to identify imaging biomarkers that might accurately predict eventual clinical success based on the observed changes in the atherosclerotic imaging measurements. With such tools as gatekeepers, only those treatments with proven efficacy during Phase II trials would be promoted to Phase III
with the expectation of high likelihood of success in the clinical endpoint trials. By enhancing the success rate of Phase III clinical trials, use of these imaging tools have the potential to accelerate the discovery of treatments for atherosclerosis.

Session program:
Overview: Why are imaging endpoints needed in CV clinical trials
Speaker: Jagat NARULA, New York, USA
Well Established Methods for Imaging Approaches: IVUS and IMT
Speaker: Jean-Claude TARDIF, Montréal, CAN
Discussant: Wolfgang KOENIG, Ulm, GER
Coronary CTA in clinical trials
Speaker: Udo HOFFMANN, Boston, USA
MRI imaging in clinical trials
Speaker: Zahi FAYAD, New York, USA
Discussant: Robin CHOUDHURY, Oxford, GBR
PET-CT imaging in clinical trials
Speaker: Ahmed TAWAKOL, Boston, USA
Discussant: James RUDD, Cambridge, GBR

Intervention
Thème
Disciplines :
Documentation
Le programme complet

Dans la même collection

Voir tout

Avec les mêmes intervenants et intervenantes

Sur le même thème